Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C. Issue 1 (5th April 2012)

• Record Type: Journal Article
• Authors: Chien, Y. H.; Peng, S. F.; Yang, C. C.; Lee, N. C.; Tsai, L. K.; Huang, A. C.; Su, S. C.; Tseng, C. C.; Hwu, W. L.
• Is Part Of: Journal of inherited metabolic disease. Volume 36:Issue 1(2013)
• Page Start: 129
• Page End: 137
• Publication Date: 2012-04-05
• Subjects: Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1007/s10545-012-9479-9
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Niemann‐Pick disease type C (NP‐C) is a rare inherited neurovisceral disease characterized by progressive neurological manifestations. Oral miglustat was first approved for the treatment of children and adults with NP‐C in Europe in 2009. There are still relatively few published data on the long‐term efficacy and safety of miglustat in patients with NP‐C in clinical practice. We report the effects of up to 6 years of treatment with miglustat 100 mg t.i.d. in five children. Overall, 3/5 patients displayed progressive dysphagia before starting miglustat, and 4/5 showed marked cognitive and/or motor impairment. The mean age at treatment start was 11.6 years, and the median (range) duration of therapy so far is 4 (4.1 to 6.1) years. No treatment dose alterations were required, but therapy was interrupted for 1–3 months at least once in all patients due to supply issues. Swallowing function was stabilised during miglustat therapy, with no significant increase in Han dysphagia scale or aspiration‐penetration index scores among four evaluable patients ( p > 0.05). Scores on the mini‐mental state examination indicated an improvement in cognitive function during the first 3–6 months of miglustat therapy, followed by stabilisation up to 5 years. Ambulatory function remained stable for at least the first 2 years of treatment in most patients, but there was a trend towards deterioration thereafter, possibly related to treatment interruptions. The safety/tolerability profile of miglustat was similar to previous clinical studies, although reports of gastrointestinal disturbances were rare. Overall, miglustat appeared to stabilise key parameters of neurological disease progression.